Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons

BACKGROUND: Until recently, treatments for older patients with AML ineligible to receive intensive chemotherapies were limited to hypomethylating agents, low-dose cytarabine (LDAC), or clinical trials. In 2018, the FDA approved combination glasdegib (GLAS) plus LDAC based on Phase II results demonst...

Descripción completa

Detalles Bibliográficos
Autores principales: Tremblay, Gabriel, Westley, Tracy, Cappelleri, Joseph C, Arondekar, Bhakti, Chan, Geoffrey, Bell, Timothy J, Briggs, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735653/
https://www.ncbi.nlm.nih.gov/pubmed/31564931
http://dx.doi.org/10.2147/CEOR.S203482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735653/
https://www.ncbi.nlm.nih.gov/pubmed/31564931
http://dx.doi.org/10.2147/CEOR.S203482

Ejemplares similares